Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly

Basit Öğe Kaydı
dc.contributor.authorTütüncü, Yasemin Ateş
dc.contributor.authorBerker, Dilek
dc.contributor.authorIşık, Serhat
dc.contributor.authorÖzuğuz, Ufuk
dc.contributor.authorAkbaba, Gülhan
dc.contributor.authorKüçükler, Ferit Kerim
dc.contributor.authorGüler, Serdar
dc.date.accessioned2020-04-30T22:41:22Z
dc.date.available2020-04-30T22:41:22Z
dc.date.issued2012
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000308817000016en_US
dc.descriptionPubMed: 21863263en_US
dc.description.abstractLong-acting somatostatin analogs are frequently used as adjuvant treatment of acromegaly patients after noncurative surgery. This sudy aims to compare the efficacy of octreotide long-acting release (OCT) and lanreotide Autogel (LAN) in acromegaly patients. Sixty-eight patients not cured by transsphenoidal endoscopic or microscopic pituitary surgery between 2003 and 2009 were retrospectively analyzed (25 men; 43 women; mean age 41.1 +/- A 10.9 years [range 18-65 years]). The patients were assigned randomly to OCT (n = 36) and LAN (n = 32) groups. Evaluations included insulin-like growth factor I (IGF-I) and growth hormone (GH) after oral glucose tolerance test (OGTT) 3, 6, 12 and 18 months after starting medical treatment; pituitary magnetic resonance imaging was performed before treatment and after 3 and 12 months. Patients achieving IGF-I levels within the age and gender normal range and GH level < 1 mu g/l following OGTT were considered a 'biochemical cure'. Mean IGF-I and GH values and tumor volumes (cm(3)) in the LAN and OCT groups were similar in the post-operative period before initiation of medical treatment. A statistically significant decrease in GH and IGF-I levels was obtained for both treatment groups at each follow-up visit compared to the previous value. Tumor shrinkage after 12 months of treatment was statistically significant in both groups but the percentage tumor shrinkage (28.5% vs. 34.9%, P = 0.166) and rate of patients achieving biochemical cure (63.9 and 78.1%, P = 0.454) were similar between OCT and LAN groups, respectively. OCT and LAN treatment options have similar efficacy for ensuring biochemical cure and tumor shrinkage in acromegaly patients who had noncurative surgery.en_US
dc.description.sponsorshipIpsen (Paris, France)en_US
dc.description.sponsorshipEditorial assistance was provided by Martin Gilmour at ESP Bioscience (Crowthorne, UK) and funded by Ipsen (Paris, France). We have not received any funding support for the study.en_US
dc.identifier.doi10.1007/s11102-011-0335-yen_US
dc.identifier.endpage404en_US
dc.identifier.issn1386-341X
dc.identifier.issn1573-7403
dc.identifier.issue3en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage398en_US
dc.identifier.urihttps://doi.org/10.1007/s11102-011-0335-y
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3174
dc.identifier.volume15en_US
dc.identifier.wosWOS:000308817000016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofPituitaryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcromegalyen_US
dc.subjectSomatostatin analogsen_US
dc.subjectOctreotideen_US
dc.subjectLanreotideen_US
dc.titleComparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegalyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
3174.pdf
Boyut:
202.59 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu